Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and comparative utility of afatinib in non-small cell lung cancer

1 Apr 2014

Abstract excerpt

The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients develop acquired resistance principally through secondary mutations (T790M), HER2 amplification, MET amplification, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to Quinazolinone synthesis and applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24790411
DOI: 10.2147/btt.s40567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and comparative utility of afatinib in non-small cell lung cancerPMID 24790411Read ↗

Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Semantic proximity Read ↗

Afatinib for the treatment of advanced non-small-cell lung cancer.Semantic proximity Read ↗

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.Semantic proximity Read ↗

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.Semantic proximity Read ↗

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Semantic proximity Read ↗

Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.Semantic proximity Read ↗

The safety of afatinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.Semantic proximity Read ↗

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

[Evidence on afatinib in patients progressing on a first-line treatment].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.